CONTACT US   |  (864) 397-5101

SC Launch, Inc. Announces $300,000 Elastrin Therapeutics Investment

Compliments of The Business Narrative

South Carolina Research Authority (SCRA’s) investment affiliate, SC Launch Inc., has invested in Elastrin Therapeutics Inc.

The $300,000 investment will help the company advance the development of therapeutics that reverse damaged tissue making it supple again, SCRA officials said.

The Simpsonville-based biotech startup developed this technology, which restores hardened or damaged arteries and tissues by targeting the elastic fiber and removing the calcification that causes stiffening. Initial applications include reducing hardened arteries, de-calcifying heart valves, and treating diabetes and COPD.

Elastrin became an SCRA Member Company in 2018 and received a $25,000 Academic Startup Grant. It also received a $50,000 Federal Matching Grant in 2019.

Elastrin became an SC Launch Inc. Portfolio Company in 2022 when it received this first investment of $300,000. It also received a $50,000 grant during SCRA’s pandemic funding round for startups providing Covid-19 solutions.

Elastrin recently closed a $10 million funding round, which included this investment.

It also recently announced the formation of its scientific advisory board, comprised of leading industry and university experts in cardiovascular research and clinical development.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.